戻る Agenda
To Err is Human: Progress and Challenges in the Prevention of Medication Errors
Session Chair(s)
Tony Catka, PHD
Director Regulatory Policy and Intelligence
Ionis Pharmaceuticals, Inc, United States
This forum will look at progress in the reduction of medication errors due to name confusion. A panel of experts, representing major health authorities and WHO will provide a concise summary of guidelines these bodies have developed to minimize these errors, discuss differences in their approaches and what they see are the challenges that remain.
Learning Objective : Discuss progress in the reduction of medication errors due to the development of regulations surrounding the development of drug names; Evaluate progress and identify challenges in the development of guidance by FDA, Health Canada, and EMA for proprietary names development and challenges with name confusion in the development of INNs; Describe best practices in the development of acceptable proprietary and non-proprietary names.
Speaker(s)
ISMP Perspective
Michael R. Cohen, DRSC, MS, RPH
Institute for Safe Medication Practices, United States
President
FDA Perspective
Lubna Merchant, PHARMD, MS
AbbVie, United States
Risk Management Strategy
WHO Perspective
Raffaella Giovanna Balocco Mattavelli, PHARMD, PHD
World Health Organization (WHO), Switzerland
Group Lead, International Nonproprietary Name Programme